**Supplementary Table 1.** First round screening: Performance of screening tests and percentage of positive results

|  |  |  |  |
| --- | --- | --- | --- |
|  | **H&P** | **H&P + ECG** | **ECG alone** |
|  | Sensitivity | Specificity | Positive results | Sensitivity | Specificity | Positive results | Sensitivity | Specificity | Positive results |
| **Fuller 2000 (13)** | 6% | 97.8% | 2.2% | - | - | - | 70% | 84.3% | 15.7% |
| **Wheeler et al. 2010 (19)** | 15%(CI: 8-25%) | 97%(CI : 92-98%) | *3%\** | 68%(CI : 50-73%) | 95%(CI : 93-97%) | *5.8%\** | 40%(CI : 25-45%) | 98%(CI : 95.2-98.8%) | *2.5%\** |
| **Leslie et al. 2012 (15)** | - | - | - | HCM : 85%WPW: 95%LQTS: 80-85% | HCM : 85%WPW: 99.9%LQTS: 60% | *HCM : 15%\***WPW: 0.14%\***LQTS: 40%\** | - | - | - |
| **Schoenbaum et al. 2012**  **(18)** | 6% (3%-40%) | 95%(85-100%) | 5% | 71% (65%-77%) | 91%(72%-100%) | 9% | 70% (65%-75%) | 95%(85%-100%) | 5% |
| **Halkin et al. 2012 (14)** | - | - | - | / | / | 9% | - | - | - |

H&P: History and physical examination; ECG: rest-electrocardiogram; HCM: Hypertrophic cardiomyopathy, LQTS: Long QT Syndrome; US: United States; WPW: Wolf-Parkinson-White; (-) not investigated; (/) not specified; \*Own calculation.